New hope for Tough-to-Treat uterine cancer in early trial
NCT ID NCT06795009
Summary
This early-stage study is testing a new drug, zanzalintinib, combined with a standard chemotherapy (paclitaxel) for people with recurrent high-grade uterine or endometrial cancer that has worsened after prior treatment. The main goal is to find the safest and most effective dose of the new combination. Researchers will also monitor how patients respond to the treatment and track side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-••••
Contact
-
University of New Mexico
NOT_YET_RECRUITINGAlbuquerque, New Mexico, 87106, United States
Contact Phone: •••-•••-••••
Contact
-
University of Oklahoma
NOT_YET_RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-••••
Contact
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.